Mabylon AG is a Schlieren-based biotechnology company at the forefront of human-derived antibody research, with a primary focus on allergies, neurological and inflammatory disorders. The company has secured three substantial grants totalling over CHF 1.3 million from various organisations including Innosuisse, Target ALS, and the ALS Association. The company…